Losartan inhibits proliferation and inflammation of vascular smooth muscle cells by modulation of uric acid transporter

seokmin kang, Woochul Chang, Soyeon Lim, Byeong Wook Song, Hye Jung Kim, Min Ji Cha, Jaewon Oh, Yangsoo Jang, Namsik Chung, Ki Chul Hwang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hyperuricemia has known to be a risk factor for coronary artery disease, hypertension, and heart failure. Among angiotensin II receptor blockers(ARBs), only losartan lowers serum uric acid(UA) level compared with other ARBs. Recent studies have reported that UAcauses vascular smooth muscle cells(VSMCs) proliferation and inflammation by entering cells via a functional uric acid transporter(UAT). We investigated whether losartan could inhibit the UA-stimulated proliferative and inflammatory signaling activation by modulation of UAT in cultured rat aortic VSMCs. Following 72 hours incubation of UA, proliferation of VSMCs was increased dose-dependently. Losartan inhibited UA-stimulatedproliferation in dose-dependent manner with an IC50 value of about 1 M. Losartan attenuatedp38, ERKs activation, COX-2 expression, and MCP-1 production. Losartan significantly decreased expression of UAT in UA-stimulated VSMCs(33% reduction, p<0.05), which suggests inhibitory effect of losartan on the uptake of UA via UAT. These data provide that losartan may involve anti-inflammatory and antiproliferative activity by modulating UAT. Therefore, losartan may provide beneficial effect on vascular changes in hyperuricemic condition.

Original languageEnglish
Pages (from-to)521-527
Number of pages7
JournalTissue Engineering and Regenerative Medicine
Volume5
Issue number3
Publication statusPublished - 2008 Sep 1

Fingerprint

Losartan
Uric Acid
Vascular Smooth Muscle
Smooth Muscle Myocytes
Muscle
Cells
Modulation
Inflammation
Acids
Angiotensin Receptor Antagonists
Chemical activation
Hyperuricemia
Cell proliferation
Inhibitory Concentration 50
Blood Vessels
Rats
Coronary Artery Disease
Anti-Inflammatory Agents
Heart Failure
Cell Proliferation

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Biomedical Engineering

Cite this

kang, seokmin ; Chang, Woochul ; Lim, Soyeon ; Song, Byeong Wook ; Kim, Hye Jung ; Cha, Min Ji ; Oh, Jaewon ; Jang, Yangsoo ; Chung, Namsik ; Hwang, Ki Chul. / Losartan inhibits proliferation and inflammation of vascular smooth muscle cells by modulation of uric acid transporter. In: Tissue Engineering and Regenerative Medicine. 2008 ; Vol. 5, No. 3. pp. 521-527.
@article{e3b95fccacc54b30abaabb8365e8cf81,
title = "Losartan inhibits proliferation and inflammation of vascular smooth muscle cells by modulation of uric acid transporter",
abstract = "Hyperuricemia has known to be a risk factor for coronary artery disease, hypertension, and heart failure. Among angiotensin II receptor blockers(ARBs), only losartan lowers serum uric acid(UA) level compared with other ARBs. Recent studies have reported that UAcauses vascular smooth muscle cells(VSMCs) proliferation and inflammation by entering cells via a functional uric acid transporter(UAT). We investigated whether losartan could inhibit the UA-stimulated proliferative and inflammatory signaling activation by modulation of UAT in cultured rat aortic VSMCs. Following 72 hours incubation of UA, proliferation of VSMCs was increased dose-dependently. Losartan inhibited UA-stimulatedproliferation in dose-dependent manner with an IC50 value of about 1 M. Losartan attenuatedp38, ERKs activation, COX-2 expression, and MCP-1 production. Losartan significantly decreased expression of UAT in UA-stimulated VSMCs(33{\%} reduction, p<0.05), which suggests inhibitory effect of losartan on the uptake of UA via UAT. These data provide that losartan may involve anti-inflammatory and antiproliferative activity by modulating UAT. Therefore, losartan may provide beneficial effect on vascular changes in hyperuricemic condition.",
author = "seokmin kang and Woochul Chang and Soyeon Lim and Song, {Byeong Wook} and Kim, {Hye Jung} and Cha, {Min Ji} and Jaewon Oh and Yangsoo Jang and Namsik Chung and Hwang, {Ki Chul}",
year = "2008",
month = "9",
day = "1",
language = "English",
volume = "5",
pages = "521--527",
journal = "Tissue Engineering and Regenerative Medicine",
issn = "1738-2696",
publisher = "Springer Science + Business Media",
number = "3",

}

Losartan inhibits proliferation and inflammation of vascular smooth muscle cells by modulation of uric acid transporter. / kang, seokmin; Chang, Woochul; Lim, Soyeon; Song, Byeong Wook; Kim, Hye Jung; Cha, Min Ji; Oh, Jaewon; Jang, Yangsoo; Chung, Namsik; Hwang, Ki Chul.

In: Tissue Engineering and Regenerative Medicine, Vol. 5, No. 3, 01.09.2008, p. 521-527.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Losartan inhibits proliferation and inflammation of vascular smooth muscle cells by modulation of uric acid transporter

AU - kang, seokmin

AU - Chang, Woochul

AU - Lim, Soyeon

AU - Song, Byeong Wook

AU - Kim, Hye Jung

AU - Cha, Min Ji

AU - Oh, Jaewon

AU - Jang, Yangsoo

AU - Chung, Namsik

AU - Hwang, Ki Chul

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Hyperuricemia has known to be a risk factor for coronary artery disease, hypertension, and heart failure. Among angiotensin II receptor blockers(ARBs), only losartan lowers serum uric acid(UA) level compared with other ARBs. Recent studies have reported that UAcauses vascular smooth muscle cells(VSMCs) proliferation and inflammation by entering cells via a functional uric acid transporter(UAT). We investigated whether losartan could inhibit the UA-stimulated proliferative and inflammatory signaling activation by modulation of UAT in cultured rat aortic VSMCs. Following 72 hours incubation of UA, proliferation of VSMCs was increased dose-dependently. Losartan inhibited UA-stimulatedproliferation in dose-dependent manner with an IC50 value of about 1 M. Losartan attenuatedp38, ERKs activation, COX-2 expression, and MCP-1 production. Losartan significantly decreased expression of UAT in UA-stimulated VSMCs(33% reduction, p<0.05), which suggests inhibitory effect of losartan on the uptake of UA via UAT. These data provide that losartan may involve anti-inflammatory and antiproliferative activity by modulating UAT. Therefore, losartan may provide beneficial effect on vascular changes in hyperuricemic condition.

AB - Hyperuricemia has known to be a risk factor for coronary artery disease, hypertension, and heart failure. Among angiotensin II receptor blockers(ARBs), only losartan lowers serum uric acid(UA) level compared with other ARBs. Recent studies have reported that UAcauses vascular smooth muscle cells(VSMCs) proliferation and inflammation by entering cells via a functional uric acid transporter(UAT). We investigated whether losartan could inhibit the UA-stimulated proliferative and inflammatory signaling activation by modulation of UAT in cultured rat aortic VSMCs. Following 72 hours incubation of UA, proliferation of VSMCs was increased dose-dependently. Losartan inhibited UA-stimulatedproliferation in dose-dependent manner with an IC50 value of about 1 M. Losartan attenuatedp38, ERKs activation, COX-2 expression, and MCP-1 production. Losartan significantly decreased expression of UAT in UA-stimulated VSMCs(33% reduction, p<0.05), which suggests inhibitory effect of losartan on the uptake of UA via UAT. These data provide that losartan may involve anti-inflammatory and antiproliferative activity by modulating UAT. Therefore, losartan may provide beneficial effect on vascular changes in hyperuricemic condition.

UR - http://www.scopus.com/inward/record.url?scp=80051963865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051963865&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:80051963865

VL - 5

SP - 521

EP - 527

JO - Tissue Engineering and Regenerative Medicine

JF - Tissue Engineering and Regenerative Medicine

SN - 1738-2696

IS - 3

ER -